Chris Hollowood

Chris Hollowood is an accomplished executive with extensive experience in the biotech and therapeutic sectors. Currently serving as a Non-Executive Director at Yellowstone Biosciences since March 2024, Chris has held the positions of Chief Executive Officer and Chief Investment Officer at Syncona Limited since September 2012. Additional leadership roles include Non-Executive Director at Beacon Therapeutics and Chairman at multiple organizations such as Freeline, Purespring Therapeutics, Mosaic Therapeutics, Forcefield Therapeutics, SwanBio Therapeutics, Gyroscope Therapeutics, and Nightstar Therapeutics. Chris Hollowood earned a PhD in Organic Chemistry and a degree in Natural Sciences, Chemistry from the University of Cambridge.